• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

PolarCool Signs Its Third Agreement in the British Elite Ice Hockey League with Manchester Storm

POLARRegulatory press release12.02.2026 klo 11.00
Download the release

The med-tech company PolarCool AB (publ.) has entered into an agreement with the professional ice hockey team Manchester Storm in the British Elite Ice Hockey League (EIHL). The club becomes the third team in the league to use PolarCap® for the acute treatment of concussions.

 

With Manchester Storm as a new customer, PolarCool further expands its presence in the British top league, which consists of a total of ten teams from England, Northern Ireland, Scotland, and Wales. PolarCool already has agreements in place with Cardiff Devils and Sheffield Steelers for the use of PolarCap®.

 

PolarCool's CEO, Erik Andersson, comments:

 

-We are very pleased that Manchester Storm have chosen to provide PolarCap®. We are seeing increasing interest in the British league, and this agreement is an indication that our solution addresses a genuine need. We see strong potential for additional EIHL clubs to follow the clubs that now already provide PolarCap®.

 

PolarCool currently has a strong customer base within European professional ice hockey, with teams using PolarCap® in top leagues across Sweden, Germany, Switzerland, Finland, Austria, France, the Czech Republic, and Slovakia. Manchester Storm will use PolarCap® for the remainder of the season during an initial evaluation period, with the possibility of continuing into a two-year commercial agreement following the evaluation. Although individual agreements may have limited financial impact, this marks an important step in PolarCool's long-term growth strategy and its ambition to strengthen its position in the European market.

 

For more information

Erik Andersson - CEO PolarCool AB (publ.) 
+46 - 73 860 57 00    
E-mail: erik.andersson@polarcool.se

 

About PolarCool AB (publ.)
PolarCool AB (publ.) is a Swedish medical technology company focused on developing and marketing products in the sports medicine field. Its primary product, PolarCap®, is designed to reduce the impact of concussion through targeted brain cooling. PolarCool works with professional teams across Europe in rugby, football, and ice hockey and its shares are listed on Spotlight Stock Market.